Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.